POXEL Stock Overview
A clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Poxel S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.55 |
52 Week High | €0.95 |
52 Week Low | €0.30 |
Beta | 1.55 |
11 Month Change | -8.60% |
3 Month Change | 5.94% |
1 Year Change | -14.92% |
33 Year Change | -92.16% |
5 Year Change | -91.77% |
Change since IPO | -92.31% |
Recent News & Updates
Recent updates
Poxel S.A. (EPA:POXEL) Analysts Just Trimmed Their Revenue Forecasts By 28%
Mar 27Is Poxel (EPA:POXEL) Weighed On By Its Debt Load?
May 07How Much Did Poxel's(EPA:POXEL) Shareholders Earn From Share Price Movements Over The Last Five Years?
Dec 16How Does Poxel's (EPA:POXEL) CEO Pay Compare With Company Performance?
Nov 17Shareholder Returns
POXEL | FR Biotechs | FR Market | |
---|---|---|---|
7D | 1.1% | -0.3% | 1.3% |
1Y | -14.9% | -28.7% | 2.3% |
Return vs Industry: POXEL exceeded the French Biotechs industry which returned -28.7% over the past year.
Return vs Market: POXEL underperformed the French Market which returned 2.3% over the past year.
Price Volatility
POXEL volatility | |
---|---|
POXEL Average Weekly Movement | 11.7% |
Biotechs Industry Average Movement | 6.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in FR Market | 9.4% |
10% least volatile stocks in FR Market | 2.6% |
Stable Share Price: POXEL's share price has been volatile over the past 3 months.
Volatility Over Time: POXEL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 15 | Thomas Kuhn | www.poxelpharma.com |
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications.
Poxel S.A. Fundamentals Summary
POXEL fundamental statistics | |
---|---|
Market cap | €26.44m |
Earnings (TTM) | -€44.24m |
Revenue (TTM) | €1.55m |
17.1x
P/S Ratio-0.6x
P/E RatioIs POXEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
POXEL income statement (TTM) | |
---|---|
Revenue | €1.55m |
Cost of Revenue | €1.54m |
Gross Profit | €2.00k |
Other Expenses | €44.24m |
Earnings | -€44.24m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Aug 29, 2024
Earnings per share (EPS) | -0.93 |
Gross Margin | 0.13% |
Net Profit Margin | -2,861.58% |
Debt/Equity Ratio | -112.1% |
How did POXEL perform over the long term?
See historical performance and comparison